MedPath

Novel Updates in Second-line Therapies for LR-MDS

Recent discussions highlight the clinical benefits of dose escalation of luspatercept in treating lower-risk myelodysplastic syndrome (LR-MDS), based on findings from the MAXILUS trial and real-world evidence presented at EHA 2024.

Recent advancements in the treatment of lower-risk myelodysplastic syndrome (LR-MDS) have been discussed, focusing on the dose escalation of luspatercept. Insights from the MAXILUS trial (Della Porta et al, EHA 2024) and real-world evidence (Patel et al, EHA 2024) were highlighted, showcasing the potential of this dosing strategy to improve patient outcomes and influence clinical practice. The discussions emphasized the importance of these findings in enhancing patient care for those with LR-MDS, marking a significant step forward in the management of this condition.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Luspatercept Plus Lenalidomide Shows Promise in Non-del(5q) Myelodysplastic Syndrome

A phase 1b trial combining luspatercept and lenalidomide demonstrates safety and preliminary efficacy in patients with non-del(5q) myelodysplastic syndrome (MDS).
The combination therapy showed a 50% hematologic improvement rate among evaluable patients, with notable red blood cell transfusion independence.

Luspatercept Demonstrates Significant Reduction in Transfusion Burden in Lower-Risk MDS Patients: COMMANDS Trial

The COMMANDS trial reveals that luspatercept significantly reduces red blood cell (RBC) transfusion burden in patients with lower-risk myelodysplastic syndromes (MDS).
Luspatercept demonstrated superior efficacy compared to erythropoiesis-stimulating agents (ESAs) in achieving transfusion independence for at least 12 weeks.

Luspatercept Plus Lenalidomide Shows Promise in Non-Del(5q) Myelodysplastic Syndromes

Initial safety findings suggest that the combination of luspatercept and lenalidomide is tolerable in patients with non-del(5q) myelodysplastic syndromes (MDS).
The study aims to address the unmet need for effective treatments in this specific MDS subgroup, which often has a poorer prognosis.

MAXILUS Trial Investigates Higher Luspatercept Dose in Lower-Risk MDS

The phase 3b MAXILUS trial (NCT06045689) is evaluating the safety and efficacy of initiating treatment with luspatercept at the maximum approved dose in patients with lower-risk myelodysplastic syndromes (MDS).
The study aims to determine if starting luspatercept at 1.75 mg/kg, instead of the standard 1 mg/kg, can improve outcomes for both ESA-naive and ESA-refractory/relapsed patients.

Brigimadlin Shows Promise in Treating Dedifferentiated Liposarcoma

Brigimadlin (BI 907828) is an oral MDM2-p53 antagonist showing potential in treating dedifferentiated liposarcoma (DDLPS) by restoring normal p53 activity.
A Phase 1a/1b study indicated brigimadlin has a manageable safety profile, with nausea being the most common adverse effect, and demonstrated stable disease in 75% of liposarcoma patients.

Recent Clinical Trial Updates and FDA Actions in Oncology: A Review

The VERONA and SELECT-MDS-1 trials are evaluating novel combinations in myelodysplastic syndromes (MDS) that could potentially shift the treatment paradigm.
Enhertu (fam-trastuzumab deruxtecan-nxki) has received priority review from the FDA for HER2-low/ultra-low breast cancer, showing promise as a targeted treatment option.

Luspatercept and Novel Therapies Reshape Treatment Strategies in Myelodysplastic Syndromes

The COMMANDS trial demonstrated that luspatercept significantly improved red blood cell transfusion independence compared to epoetin alfa in patients with low-risk MDS.
Imetelstat has shown promise in patients with prior ESA treatment, exhibiting a 34% transfusion independence rate, potentially modifying the disease course by reducing mutation burden.

Luspatercept Improves Quality of Life in First-Line Treatment of Anemia in Lower-Risk MDS

Luspatercept's approval offers an effective and well-tolerated first-line treatment for anemia in lower-risk myelodysplastic syndrome (MDS) patients without prior ESA use.
The COMMANDS trial demonstrated luspatercept's significant advantage over ESAs in treating anemia, leading to improved fatigue and overall quality of life (QOL) for patients.

Luspatercept Demonstrates Superior Efficacy in Frontline Treatment of Lower-Risk MDS

Luspatercept gains FDA approval as a frontline treatment for anemia in lower-risk myelodysplastic syndrome (MDS) patients without prior erythropoiesis-stimulating agent (ESA) use.
The COMMANDS trial demonstrated that luspatercept achieved higher rates of red blood cell transfusion independence and hemoglobin increase compared to epoetin alfa.

Advancements in Higher-Risk MDS Treatment Strategies Explored

Allogeneic transplantation remains the only curative option for high-risk myelodysplastic syndrome (HR-MDS) patients, but post-transplant relapse is still a problem.
Combinations of azacitidine with drugs like lenalidomide and durvalumab have not demonstrated a survival benefit over azacitidine monotherapy in phase 3 trials.

Reference News

[1]
Novel Updates in Second-line Therapies for LR-MDS - Targeted Oncology
targetedonc.com · Jan 8, 2025

Panelists review luspatercept dose escalation in LR-MDS, noting its clinical benefits from the MAXILUS trial, and discus...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy